person
as of 2026-07-01Caroline Ward, PhD.
ORCID 0000-0003-4857-7397
at a glance
Roles: Study Director, Author
KOL signal score 13
6 publications · 3 high-value
Cross-drug reach: 1 competitor drugs
Synthesized from structured facts only — each point cited above.
Profile
Affiliation
Otsuka Pharmaceutical Development & Commercialization, Inc.
Roles
Study Director, Author
KOL signal
13
Publications
6 (3 high-value)
Trial investigator
no
Publishes on
1 drugs
Trials led
1
Publications & congress
6
Effects of Adjunctive Brexpiprazole in Major Depressive Disorder Analyzed by Baseline Anxiety Level: Post Hoc Analysis of a Phase 4 Study.
Journal of clinical psychopharmacology · 2026 Mar-Apr 01 · high-value
Efficacy and safety of brexpiprazole in adolescents with schizophrenia: a multicountry, randomised, double-blind, placebo-controlled, phase 3 trial with an active reference.
The lancet. Psychiatry · 2025 · high-value
Safety and Efficacy of Brexpiprazole in the Treatment of Irritability Associated with Autism Spectrum Disorder: An 8-Week, Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial and 26-Week Open-Label Extension in Children and Adolescents.
Journal of child and adolescent psychopharmacology · 2025 · high-value
Benefits and safety of brexpiprazole in adolescents living with schizophrenia: a plain language summary.
Current medical research and opinion · 2026
Patient-reported efficacy of adjunctive brexpiprazole in major depressive disorder in a phase 4, open-label, interventional study.
Current medical research and opinion · 2025
Safety and Tolerability of Brexpiprazole in Adolescents With Schizophrenia: A Long-Term, Open-Label Study.
JAACAP open · 2025
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here